To date, there was no solid evidence that gefitinib or erlotinib had less efficacy than afatinib in first-line treatment of patients with EGFR-mutant lung adenocarcinoma and brain metastases [1–4, 12]. The gene discussed is EGFR; the disease is lung adenocarcinoma.